Aim: This study compared the hematopoietic capacities of erythropoietin (Epo) and
antioxidant drug U-74389G, based on 2 preliminary studies. The provided results on hematocrit levels
augmentation were co-evaluated in a hypoxia reoxygenation protocol of an animal model.
Materials and Methods: Hematocrit levels were evaluated at the 60th reoxygenation min (for groups
A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B
received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E
and F were administered with U-74389G.
Results: The first preliminary study of Epo non-significantly increased the hematocrit levels by
0.24%+1.38% (p-value=0.8586). The second preliminary study of U-74389G significantly raised the
hematocrit levels by 3.16%+1.33% (p-value=0.0196). These 2 studies were co-evaluated since they came
from the same experimental setting. The outcome of the co-evaluation was that U-74389G has
approximately 12.66-fold higher hematopoietic potency than Epo (p-value=0.0000).
Conclusion: The anti-oxidant capacities of U-74389G provide satisfactory acute hematopoietic
properties; presenting approximately 12.66-fold hematocrit level rise than epo (p-value=0.0000).